Defining effective antitumor T cell responses to guide next-generation adoptive

Wednesday 09:00 PST / 12:00 EST / 17:00 GMT / 18:00 CET

Sponsor

Defining effective antitumor T cell responses to guide next-generation adoptive

Drawing on longitudinal patient data and functional validation studies, Cristina Puig-Saus (Assistant Professor, UCLA) will show how immunodominance, T cell polyclonality, and TCR persistence inform the identification of effective tumor-reactive T cells.

She will then connect these biological insights to practical strategies for TCR discovery, endogenous TCR replacement, and fine-tuning CAR-T design.

This webinar will:

Provide a blueprint for isolating patient-specific TCRs even in "non-responders," opening new avenues for personalized adoptive cell therapy (ACT)
Explain how persistence and recurrence of TCR clonotypes impact resistance to checkpoint inhibitors
Describe advances methods for tuning CAR-T sensitivity to safely target low-density surface antigens without triggering off-tumor toxicity
Address the critical challenges of the immunosuppressive TME and T-cell exhaustion by focusing on TCR replacement and high-sensitivity CAR-T designs
Describe real-life experience of moving a novel CAR-T therapy from preclinical modeling into a Phase I clinical trial protocol

Register today to gain data-driven insights into T cell biology and engineering strategies that inform the design of next-generation adoptive cell therapies for solid tumors.

Cristina Puig-Saus, PhD

Assistant Professor, Department of Microbiology, Immunology, and Molecular Genetics; Department of Surgery, Division of Surgical Oncology at UCLA

Dr. Cristina Puig Saus' research efforts are mainly focused on the understanding of natural T cell responses to cancer and the design and clinical translation of new cellular therapies for solid tumors. Her lab is currently studying the neoepitope-specific T cell responses induced after immune checkpoint blockade in patients that respond or do not respond to therapy, with the objective to define what constitutes an effective antitumor T cell response. They are also interested in developing novel CAR-T cell therapies for melanoma. They are currently starting the IND-enabling studies for one of their candidates and in parallel designing additional CAR-T cell based strategies and combination therapies. Her additional interests include the design of strategies to improve T cell gene editing for their use in adoptive T cell therapy for cancer.

In 35 Days

You have registered for this webinar